1. Home
  2. COLL vs PLPC Comparison

COLL vs PLPC Comparison

Compare COLL & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • PLPC
  • Stock Information
  • Founded
  • COLL 2002
  • PLPC 1947
  • Country
  • COLL United States
  • PLPC United States
  • Employees
  • COLL N/A
  • PLPC N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • PLPC Water Sewer Pipeline Comm & Power Line Construction
  • Sector
  • COLL Health Care
  • PLPC Industrials
  • Exchange
  • COLL Nasdaq
  • PLPC Nasdaq
  • Market Cap
  • COLL 958.8M
  • PLPC 789.5M
  • IPO Year
  • COLL 2015
  • PLPC N/A
  • Fundamental
  • Price
  • COLL $38.32
  • PLPC $192.13
  • Analyst Decision
  • COLL Strong Buy
  • PLPC
  • Analyst Count
  • COLL 4
  • PLPC 0
  • Target Price
  • COLL $44.25
  • PLPC N/A
  • AVG Volume (30 Days)
  • COLL 427.8K
  • PLPC 54.6K
  • Earning Date
  • COLL 08-07-2025
  • PLPC 10-29-2025
  • Dividend Yield
  • COLL N/A
  • PLPC 0.42%
  • EPS Growth
  • COLL N/A
  • PLPC 5.07
  • EPS
  • COLL 1.06
  • PLPC 8.56
  • Revenue
  • COLL $707,007,000.00
  • PLPC $632,231,000.00
  • Revenue This Year
  • COLL $22.23
  • PLPC N/A
  • Revenue Next Year
  • COLL $2.78
  • PLPC N/A
  • P/E Ratio
  • COLL $36.58
  • PLPC $22.20
  • Revenue Growth
  • COLL 22.61
  • PLPC 7.95
  • 52 Week Low
  • COLL $23.23
  • PLPC $109.01
  • 52 Week High
  • COLL $42.29
  • PLPC $197.56
  • Technical
  • Relative Strength Index (RSI)
  • COLL 59.51
  • PLPC 64.10
  • Support Level
  • COLL $38.00
  • PLPC $186.75
  • Resistance Level
  • COLL $39.78
  • PLPC $197.56
  • Average True Range (ATR)
  • COLL 0.97
  • PLPC 5.44
  • MACD
  • COLL -0.18
  • PLPC -0.32
  • Stochastic Oscillator
  • COLL 38.72
  • PLPC 73.59

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About PLPC Preformed Line Products Company

Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.

Share on Social Networks: